Sales & Support: +86 15190047243
  • linkedIn
English
English French German Portuguese Spanish Russian Japanese Korean Arabic Turkish Italian Indonesian Polish Hindi Dutch Malay Persian Thai Vietnamese
Inquiry
Form loading...
Products Categories
Featured Products
Upadacitinib (Crystal Form C)
Upadacitinib (Crystal Form C)
Isoquinoline
Isoquinoline
Information
Information
Quinoline
Quinoline
Netupitant
Netupitant
N-methyl-6-(4-methylpiperazin-1-yl)-4-(o-tolyl)pyridin-3-amine
N-methyl-6-(4-methylpiperazin-1-yl)-4-(o-tolyl)pyridin-3-amine
2-(3,5-bis(trifluoroMethyl)phenyl)-2-Methyl propanoic acid
2-(3,5-bis(trifluoroMethyl)phenyl)-2-Methyl propanoic acid
Lefamulin acetate
Lefamulin acetate
tert-butyl ((1R,3R,4R)-3-hydroxy-4-mercaptocyclohexyl)carbamate
tert-butyl ((1R,3R,4R)-3-hydroxy-4-mercaptocyclohexyl)carbamate
(3aR,4R,5R,7S,8S,9R,9aS,12R)-8-hydroxy-4,7,9,12-tetramethyl-3-oxo-7-vinyldecahydro-4,9a-propanocyclopenta[8]annulen-5-yl 2-(tosyloxy)acetate
(3aR,4R,5R,7S,8S,9R,9aS,12R)-8-hydroxy-4,7,9,12-tetramethyl-3-oxo-7-vinyldecahydro-4,9a-propanocyclopenta[8]annulen-5-yl 2-(tosyloxy)acetate
0102030405
Sparsentan.jpg

High-Quality Sparsentan API from Trusted China Suppliers & Leading Factory for Pharmaceutical Manufacturing

Basic Information

Discover the exceptional quality and value of our products sourced directly from leading China suppliers. Our factory employs advanced manufacturing techniques to ensure that each item meets the highest standards of durability and performance. By choosing us, you are partnering with a reputable China supplier committed to excellence and customer satisfaction. Experience the difference that comes with products crafted in our state-of-the-art factory. Explore our collection today and see why we are the preferred choice for quality and reliability in the industry
  • Generic Name Sparsentan
  • Chemical Name (Dual Endothelin-Vasopressin Receptor Antagonist) – A novel small-molecule therapeutic with combined endothelin receptor type A (ETA) and angiotensin II subtype 1 (AT1) antagonism.
  • Molecular Formula C34H34FN5O6S2
  • Molecular Weight 699.79 g/mol
  • Pharmacological Class Dual-acting endothelin-angiotensin receptor antagonist (DEARA)
  • Administration Route Oral (tablets/capsules)
Contact us
Product Details

Key Therapeutic Functions
🎯 Primary Indication

Treatment of rare renal disorders, including focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN), characterized by proteinuria and progressive loss of kidney function.

⚙ Mechanism of Action

Dual Inhibition: Simultaneously blocks ETA receptors (reducing vasoconstriction, inflammation, and fibrosis) and AT1 receptors (lowering blood pressure and glomerular pressure).

Synergistic Effect: Combats pathogenic pathways in rare glomerular diseases by reducing proteinuria, preserving podocyte integrity, and delaying renal fibrosis.

📊 Clinical Efficacy

Proven to significantly reduce proteinuria (up to 40–50% in clinical trials) compared to single-target therapies.

Demonstrated renal protective effects, slowing the progression to end-stage renal disease (ESRD).

Reduces Proteinuria 40–50% Preserves Podocyte Integrity Delays Renal Fibrosis Slows ESRD Progression
Technical Specifications
Dosage Forms Film-coated tablets (e.g., 200 mg, 400 mg strengths).
Pharmacokinetics High oral bioavailability with linear absorption.
Metabolized primarily via hepatic CYP450 enzymes (CYP3A4/5, CYP2C8).
Storage Store at controlled room temperature (20–25°C), protected from moisture and light.
Shelf Life 24 months under recommended storage conditions.
Therapeutic Applications
🔬 Rare Kidney Diseases

FSGS: Targets podocyte injury and glomerular sclerosis in steroid-resistant patients.

IgA Nephropathy: Reduces mesangial proliferation and immune complex deposition.

Potential Expansion: Investigated for other proteinuric kidney diseases (e.g., diabetic nephropathy, membranous nephropathy).

FSGS IgA Nephropathy Diabetic Nephropathy Membranous Nephropathy
Clinical & Safety Profile
✅ Approvals

Granted Orphan Drug Designation (ODD) and Fast Track status by the FDA for FSGS/IgAN.

🛡 Safety

Well-tolerated in trials; common adverse effects include peripheral edema, hypotension, and hyperkalemia (managed via dose adjustment).

📋 Monitoring

Regular renal function and electrolyte assessments recommended during therapy.

Why Sparsentan Stands Out?

Sparsentan represents a paradigm shift in rare nephrology by addressing dual pathogenic pathways with a single molecule. Its precision-engineered design ensures potent efficacy in reducing proteinuria and preserving renal function, offering hope for patients with limited treatment options. Backed by rigorous clinical evidence and robust manufacturing standards, Sparsentan is positioned as a breakthrough therapy for debilitating glomerular diseases.

Frequently Asked Questions (FAQ)
Q What conditions is Sparsentan approved to treat?
Sparsentan has been granted Orphan Drug Designation (ODD) and Fast Track status by the FDA for the treatment of focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN). It is also being investigated for other proteinuric kidney diseases such as diabetic nephropathy and membranous nephropathy.
Q How does Sparsentan work differently from other kidney disease treatments?
Sparsentan employs a dual inhibition mechanism, simultaneously blocking ETA receptors and AT1 receptors. This synergistic approach targets two major pathogenic pathways at once — reducing vasoconstriction, inflammation, fibrosis, and glomerular pressure — which single-target therapies cannot achieve as effectively.
Q How effective is Sparsentan in reducing proteinuria?
Clinical trials have demonstrated that Sparsentan can significantly reduce proteinuria by up to 40–50% compared to single-target therapies. It has also shown renal protective effects by slowing the progression toward end-stage renal disease (ESRD).
Q What are the available dosage forms and strengths of Sparsentan?
Sparsentan is available as film-coated tablets in strengths of 200 mg and 400 mg. It offers high oral bioavailability with linear absorption and is metabolized primarily via hepatic CYP450 enzymes (CYP3A4/5, CYP2C8).
Q What are the common side effects and how are they managed?
Sparsentan is generally well-tolerated. The most commonly reported adverse effects include peripheral edema, hypotension, and hyperkalemia. These are typically managed through dose adjustment and regular monitoring of renal function and electrolyte levels during the course of therapy.
Q How should Sparsentan be stored and what is its shelf life?
Sparsentan should be stored at a controlled room temperature of 20–25°C, protected from moisture and light. Under these recommended storage conditions, the product maintains its stability for up to 24 months.

Leave Your Message